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Monitoring Congestive Heart Failure 
Melanie Hezzell graduated from the University of Cambridge in 1997 and worked in mixed 
and small animal practice for 10 years, during which time she gained the RCVS Certificates 
in Veterinary Diagnostic Imaging and Veterinary Cardiology. In 2007 she undertook a 
rotating small animal internship at the RVC, followed by a PhD in the identification of 
prognostic indicators in myxomatous mitral valve disease at the same institution. She then 
embarked upon a residency at the University of Pennsylvania, gaining her Diploma in 
Veterinary Cardiology in 2016.  Since then she has been a Senior Lecturer in Cardiology at 
the University of Bristol.  She is interested in all aspects of cardiology, but particularly in 
myxomatous mitral valve disease and the clinical usefulness of biomarkers. 
 
 
Congestive heart failure (CHF) is a clinical syndrome, which is commonly encountered in 
small animal practice. It is characterised by the accumulation of fluid as a result of severe 
heart disease. This fluid accumulation manifests as pulmonary oedema in left sided CHF and 
in cavitary effusions (pleural, pericardial and ascites) in right sided CHF. The clinical 
consequences of both CHF itself and its medical management can have a significant impact 
on the patient’s welfare; appropriate monitoring is therefore crucial to maintaining a good 
quality of life. This article reviews the goals of monitoring in CHF and discusses the methods 
available in veterinary practice. 
 
Introduction 
Congestive heart failure (CHF) results from the increased left and/or right atrial pressures that 




atrial pressures differ according to the underlying heart disease; in myxomatous mitral valve 
disease (MMVD) the cause is mitral regurgitation, in dilated cardiomyopathy (DCM) it is 
systolic dysfunction and in hypertrophic and restrictive cardiomyopathies (HCM and RCM, 
respectively) diastolic dysfunction results in impaired atrial emptying. Regardless of the 
underlying cause, however, increased left and/or right atrial pressures result in increased 
pulmonary and/or systemic venous pressures, respectively. The resultant increase in venous 
hydrostatic pressure favours accumulation of fluid in the extravascular space (Figure 1); this 
is initially compensated for by increased lymphatic clearance, but once this is overwhelmed 
pulmonary oedema and/or cavitary effusions develop. 
   Regardless of the underlying heart disease, the main goal of treatment for CHF is therefore 
to decrease atrial pressures and thereby decrease the venous hydrostatic pressures driving 
fluid accumulation. This is achieved primarily by treatment with diuretics, which decreases 
circulating volume by increasing urinary salt and water loss, thus decreasing cardiac preload. 
Treatment with ACE inhibitors may further decrease preload, by blunting the renin-
angiotensin-aldosterone system, while also decreasing afterload, through their vasodilatory 
effects. Although some heart diseases are associated with specific treatment considerations 
(e.g. positive inotropes such as pimobendan should be avoided in cases with outflow tract 
obstructions such as subaortic stenosis), the cornerstone of treatment remains diuresis. 
Similarly, the goals of monitoring are similar regardless of the underlying heart disease. 
 
General Monitoring Considerations 
Reported survival times for veterinary patients with CHF vary markedly between studies, 
with much of this variation attributable to differences in treatments (e.g. in one study, median 




longer than in those treated with benazepril (Haggstrom, Boswood et al. 2008)). 
Nevertheless, it seems reasonable to assume that optimal patient monitoring will also 
improve both quality of life and survival times, although there is no published data to support 
this. The overall goals of monitoring in CHF are as follows: 
i) To ensure that congestion is well controlled and the clinical consequences of 
pulmonary oedema/ cavitary effusions are minimised 
ii) To ensure that any negative consequences of medical therapy are minimised 
iii) To ensure that other consequences of severe cardiac disease (e.g. cardiac 
cachexia, arrhythmias, decreased cardiac output, etc.) are identified and 
addressed 
Clearly, the first two of these goals require a delicate balance to be struck. The best way to 
minimise the negative consequences of medical therapy is to minimise the doses of the drugs 
used; however, the doses chosen need to be adequate to control congestion. Like Goldilocks, 
we therefore need to find the dose that is “just right” for our patient. However, this decision is 
complicated by the fact that the optimal dose will vary according to individual patient 
responses to drugs (especially diuretics) and with disease severity. It is important to 
remember that dose escalations are typically required as the underlying disease progresses 
and becomes increasingly difficult to control over time.  
a) Response to Diuretics 
A range of factors influence the response of an individual patient to diuretics. Firstly, loop 
diuretics, such as furosemide, need to be delivered to the renal tubule in order to have 
their action and the oral bioavailability of furosemide is low. It is reported to be 77% in 
healthy dogs (El-Sayed, Atef et al. 1981), but in dogs with CHF this will be further 




perfusion. As a result, the clinician cannot be certain what proportion of the dose 
administered is actually reaching the renal tubule. Additionally, a phenomenon known as 
diuretic resistance develops in response to diuretic therapy. Briefly, the mechanisms of 
diuretic resistance include: 
i) Activation of the renin-angiotensin-aldosterone system (RAAS), resulting in 
increased salt and water retention 
ii) Increased proximal tubular reabsorption of salt and water due to the diuretic-
induced decrease in extracellular volume 
iii) Increased solute delivery to the distal nephrons results in their hypertrophy, 
allowing compensatory increases in reabsorption 
iv) The kidneys become less responsive to the natriuretic peptides, which are released 
by the heart in response to increased filling pressures and normally result in 
increased natriuresis and diuresis. 
Diuretic resistance develops within 14 days of treatment with furosemide in healthy dogs 
(Hori, Ohshima et al. 2010); its impact on the dose of furosemide required to control 
congestion in clinical patients is difficult to assess, but it is likely to contribute to the need 
to escalate therapy over time. 
Torasemide is a loop diuretic with a potency approximately 10 times that of furosemide. 
It also has a longer half-life and duration of action and higher bioavailability (80-100%) 
compared with furosemide (Hori, Takusagawa et al. 2007). These characteristics mean 
that torasemide produces more reliable diuresis and is better able to counteract diuretic 
resistance, although  its potency means that the risk of adverse effects is potentially 
higher.  




The majority of the adverse drug effects seen in animals being treated for CHF relate to 
diuretic therapy.  These include: 
i) Dehydration - which, if excessive, may result in decreased cardiac output and 
hypotension due to the resultant decrease in preload 
ii) Hypokalaemia and hypomagnesaemia – which may result in muscle weakness and 
arrhythmias. Spironolactone, an aldosterone receptor antagonist, is a potassium-
sparing diuretic which can help mitigate hypokalaemia. 
iii) Azotaemia – a mild pre-renal azotaemia secondary to mild dehydration is 
common and should not be a cause for concern. As a rough guide, this would 
include increases in BUN of up to 50% above the upper reference interval and 
increases in creatinine of up to 25% above the upper reference interval. However, 
more aggressive diuresis can result in acute kidney injury and/or exacerbation of 
existing chronic kidney disease 
iv) RAAS activation – this can result in increased salt and water retention, 
sympathetic activation and vasoconstriction (which increases afterload and 
therefore cardiac work). In experimental models, RAAS activation is also 
associated with adverse cardiac remodelling and the development of fibrosis. 
v) Ototoxicity – although this side-effect is listed in many formularies, it is rarely 
seen in dogs and cats. 
Adverse effects associated with angiotensin converting enzyme inhibitors (ACEi) include 
hypotension, azotaemia and hyperkalaemia, although the latter is rarely encountered in 
animals receiving loop diuretics. Pimobendan is generally well-tolerated, although 




tachycardiac or experience a decrease in systemic blood pressure (BP) (although this is 
most likely at doses significantly above the recommended range). 
From the above it is clear that monitoring of hydration status, BP, renal parameters and 
electrolytes is crucial in patients being treated for CHF.  
c) Cardiac Cachexia 
Cardiac cachexia is characterised by loss of muscle mass, with or without overall weight 
loss, as a result of decreased energy intake, increased protein catabolism, decreased 
muscle protein synthesis and increased energy requirements. Cardiac cachexia is 
associated with decreased survival times in both dogs and cats with CHF (Ineson, 
Freeman et al. 2019, Santiago, Freeman et al. 2020). Monitoring of appetite, body and 
muscle condition scores and body weight is therefore recommended. Interventions to 
improve appetite (e.g. to address drug-induced anorexia) and to maintain adequate caloric 
and protein intake (e.g. avoiding low-protein diets, where possible) should be made 
proactively. 
d) Specific Considerations for Monitoring of Cats 
HCM is by far the most common heart disease in cats (Payne, Brodbelt et al. 2015). Both 
HCM and RCM are characterised by diastolic dysfunction, which results in impaired 
cardiac filling. The time spent in diastole (and hence the time available for ventricular 
filling) shortens disproportionately to the time spent in systole as heart rates increase. 
Diastolic function will therefore be further impaired in cats with HCM or RCM when 
sympathetic tone increases, leading to further increases in left atrial pressures and a 
significant risk of decompensation of CHF. This means that a cat that has been well 
controlled in their home environment may decompensate when exposed to the stress of 




remotely and only recommend blood tests, etc. if there has been a change in medication 
doses and/or clinical status (rather than at pre-specified intervals) may be in their best 
interests. 
 
Methods for Monitoring Congestive Heart Failure 
a) Sleeping Respiratory Rate 
An ideal monitoring method would be accurate, cost-effective and readily available; 
criteria that are fulfilled by monitoring of sleeping respiratory rate (SRR) in patients with 
CHF. SRR is more accurate than resting respiratory rate, as respiratory rate is more likely 
to be influenced by the environment when animals are awake. Most dogs and cats with 
medically well-controlled CHF have SRR < 30 breaths /minute, when counted by their 
owners in their home environment (Porciello, Rishniw et al. 2016). Anecdotally, it 
appears that involving owners in this way gives them a valuable sense of ownership and 
partnership in optimising their pet’s care. Use of smartphone apps, such as the Cardalis 
App, makes the process of counting breaths per minute more straightforward (a breath is 
logged each time the user touches the smartphone screen) and also makes the following of 
trends over time easier. However, some owners prefer a paper-based log system, or to 
create their own spreadsheets.  
   Given the potential adverse effects of the drugs used to manage CHF outlined above, 
ideally the lowest effective doses (i.e. the minimum doses that control congestion) should 
be chosen. This is most important in relation to the loop diuretics; these drugs contribute 
significantly to the potential adverse effects seen and they have wide dose ranges, 
allowing the dose to be tailored to the needs of the patient. In contrast, the doses of most 




relatively standardised and less likely to be adjusted than those of the loop diuretics. SRR 
can be used to help the clinician and the owner determine the lowest effective dose of the 
loop diuretic. This is achieved by asking the owners to sequentially reduce the loop 
diuretic dose every 3-5 days while vigilantly monitoring SRR; if the SRR starts to 
increase, the dose should revert to that prior to the most recent dose reduction. 
   The author recommends that owners start to monitor SRR in dogs and cats with known 
heart disease once they develop evidence of cardiomegaly (e.g. left or right atrial 
enlargement). This is a valuable way to identify the development of CHF at the earliest 
possible opportunity. Early identification allows early intervention, so that medical 
control of CHF may be achieved before animals become dangerously dyspnoeic and 
unstable. As well as improving patient quality of life, this early intervention can result in 
significant financial savings for the owners by minimising the length of hospitalisation. 
However, in some cases (especially in cats) there is no clinical evidence of underlying 
heart disease prior to the onset of CHF, and so pre-emptive monitoring of SRR is not 
always possible. Once an animal is stabilised on medical therapy for CHF, the author 
recommends daily monitoring of SRR. If the SRR is suddenly and persistently >40 
breaths/ minute the author recommends that the owner give an additional dose of diuretics 
and contact a veterinary surgeon. If the SRR is trending consistently upwards over several 
days, the author recommends that the client contacts a veterinary surgeon before making 
any dose adjustments. 
b) Blood Tests 
As mentioned above, the monitoring of hydration status, renal parameters and electrolytes 
is crucial in patients being treated for CHF. Additionally, circulating N-terminal pro-B-
type natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) can be measured as 




i) Packed cell volume and total solids (PCV/TS) – measurement allows assessment of 
the degree of dehydration. Modest increases in PCV and TS are expected in response 
to diuretic therapy, as the goal is to decrease circulating volume in order to improve 
congestion. However, excessive dehydration is counterproductive, potentially leading 
to greater RAAS activation, azotaemia, etc. 
ii) Renal parameters – measurement of BUN and creatinine is most commonly used to 
monitor the renal effects of treatment for CHF. It is important to remember that 
diuretics have their effects by compromising the ability of the renal tubules to 
concentrate urine; urinary specific gravity (USG) will therefore be decreased in 
animals receiving treatment for CHF and USG cannot be used to assess underlying 
renal function in these patients. A mild prerenal azotaemia is a commonly anticipated 
change, secondary to dehydration, as described above. This often manifests as a mild 
increase in serum BUN, often with little change in serum creatinine.  However, the 
development of a more marked azotaemia is a cause for concern (especially if the 
increases in BUN and creatinine are rapid, if the patient has known underlying 
chronic kidney disease (CKD), or if the patient is showing clinical signs referable to 
uraemia (nausea, inappetence, vomiting, etc.). Management in such cases often 
involves a careful balance between achieving sufficient diuresis to control congestion 
while minimising the impact of therapy on renal perfusion. It is often possible to 
address this by withdrawing ACEi treatment and reducing diuretics to the lowest 
effective dose (see SRR section above). In cases with sudden onset uraemic signs and 
marked, rapid increases in BUN and creatinine, consistent with an acute kidney injury 
(AKI), diuretic and ACEi therapy may need to be withdrawn completely, at least 
temporarily; in some cases, fluid administration may be required (careful enteral 




fluid administration). In some cases, especially those that have sustained an AKI or 
with pre-existing CKD, it may not be possible to find a balance between congestion 
and uraemia that allows an acceptable quality of life, and so euthanasia may be the 
most appropriate course of action.  
iii) Electrolytes – generally, sodium, potassium and chloride are routinely monitored in 
dogs and cats being treated for CHF. Although hypomagnesaemia may result from 
diuretic therapy and may increase the risk of arrhythmias, its measurement is typically 
only considered if severe arrhythmias develop, as this test is less widely available. As 
mentioned previously, the most common electrolyte abnormality associated with loop 
diuretic and ACEi treatment is hypokalaemia, which may result in muscle weakness 
and arrhythmias (severe hypokalaemia is associated with ventricular arrhythmias, 
including ventricular tachycardia). If hypokalaemia develops, management options 
include decreasing loop diuretics to the lowest effective dose (see SRR section 
above), addition of spironolactone to the treatment regimen (if the patient is not 
already receiving this drug), withdrawal of ACEi, oral supplementation of potassium, 
or a combination of these strategies. Dilutional hyponatraemia may develop in 
patients with severe CHF, due to increased antidiuretic hormone release and 
insufficient tubular flow through the distal nephron. Although it is generally 
recommended that care is taken with salt intake in patients with heart disease (e.g. 
feeding a diet with a healthy salt content and avoiding salty treats), it may be 
necessary to supplement the diet with salt if dilutional hyponatraemia develops. 
Additionally, it should be remembered that markedly salt restricted diets tend to be 
unappetising, which can exacerbate cardiac cachexia. 
iv) Cardiac biomarkers – both NT-proBNP and cTnI have been shown to be useful in the 




CHF in both dogs and cats (Hezzell, Boswood et al. 2012, Borgeat, Payne et al. 2014, 
Fox, Oyama et al. 2015, Hezzell, Rush et al. 2016). However, their usefulness for 
monitoring of CHF is less well characterised. It appears that SRR is a more useful 
method of monitoring for worsening CHF than circulating NT-proBNP measurements 
(Schober, Hart et al. 2011); SRR has the added advantage of being achievable by the 
owner in their home environment, as frequently as they wish, without incurring any 
financial cost. NT-proBNP measurements have also been used to guide therapy in 
human CHF patients, with the goal of improving outcome. An observational study of 
dogs with CHF showed that those with lower plasma NT-proBNP measurements 
following initial treatment for CHF had longer survival times (Wolf, Gerlach et al. 
2012), and a second study showed that the use of a prespecified treatment algorithm 
results in decreases in plasma NT-proBNP (Hezzell, Block et al. 2018). However, 
whether the use of this algorithm to guide therapy results in improved outcomes in 
dogs remains unknown. It is also important to remember that there is significant day-
to-day and week-to-week variability in plasma NT-proBNP measurements in an 
individual patient, such that values must change by at least 60% before a true change 
can be considered to have occurred (Winter, Saunders et al. 2017). 
c) Blood pressure monitoring 
As mentioned above, hypotension is a potential consequence of treatment with diuretics, 
ACEi and, rarely, pimobendan. Additionally, low output failure (i.e. compromised cardiac 
output) may develop as a result of diseases associated with systolic dysfunction (e.g. 
DCM, arrhythmogenic cardiomyopathy (ARVC) and end-stage disease of any aetiology), 
severe outflow tract obstruction (e.g. subaortic stenosis) or severe diastolic dysfunction 
leading to sufficient compromise of preload. Monitoring of non-invasive BP 




important in patients receiving treatment for CHF, with a goal of maintaining systolic BP 
>100 mmHg. Non-invasive measurement using either Doppler sphygmomanometry 
(systolic BP) or the oscillometric method (systolic, diastolic and mean BP) is available 
(Figure 2). Options to address hypotension include decreasing the doses of loop diuretics 
to the lowest effective dose (see SRR section above), withdrawal of ACEi therapy, 
increasing the dose of pimobendan (if the cause is believed to be compromised systolic 
function some veterinary cardiologists will increase the dose of pimobendan by 50%, 
although it is important to note that this recommendation is off license). If in hospital 
treatment is required, pressors (e.g. dobutamine) can be used to maintain perfusion; 
however, if systolic BP >100 mmHg cannot be maintained outside the hospital 
environment and the patient’s quality of life is compromised, euthanasia should be 
considered for the welfare of the patient. 
d) Radiography 
The author does not recommend routine thoracic radiography at pre-specified intervals, 
although the initial diagnosis of CHF should be radiographically confirmed in all patients, 
unless it is not safe to do so (e.g. it is often unsafe to restrain severely dyspnoeic cats for 
radiographs) (Figure 3). Instead, radiographs are taken if the patient’s clinical status has 
changed and the underlying cause is uncertain (e.g. an increase in SRR does not respond 
to an increase in diuretic dose as expected, or an animal starts to cough without an 
increase in SRR). It is important to keep an open mind and not assume that changes in 
respiratory signs are necessarily attributable to worsening CHF; many dogs and cats with 
heart disease have concurrent airway disease, and other differentials (e.g. neoplasia, 





The prevalence of arrhythmias in dogs and cats varies widely according to the underlying 
heart disease. For example, ventricular arrhythmias are a cardinal feature of ARVC, but 
are documented far less frequently in dogs with MMVD. The author recommends that an 
electrocardiogram (ECG) is recorded in any patient in which an abnormal rhythm and/ or 
pulse deficits is appreciated on physical examination. Additionally, an ECG should be 
recorded if clinical signs potentially explained by a persistent or intermittent arrhythmia 
are reported (e.g. weakness, syncope, etc.). In the case of an intermittent arrhythmia a 
Holter monitor (allowing recording of an ECG in the patient’s normal environment for 24 
hours or more) may be required to document the rhythm at the time of an episode (e.g. of 
syncope) (Figure 4). A Holter monitor is also useful to assess and monitor the 
effectiveness of antiarrhythmic medication (e.g. to assess the adequacy of rate control in 
patients with atrial fibrillation, or the frequency of ventricular arrhythmias in patients 
with ARVC).  
f) Echocardiography 
In current veterinary practice, echocardiography is the central modality used for the 
diagnosis and staging of heart disease in dogs and cats. It allows cardiac structure and 
function to be assessed in real time and the identification of risk factors for future adverse 
events, such as the onset of CHF (e.g. left atrial enlargement and increased filling 
pressures) or arterial thromboembolism (e.g. left atrial enlargement, decreased left atrial 
function and the presence of spontaneous echocontrast +/- intracardiac thrombus). 
However, once the underlying heart disease has been characterised and the presence of 
CHF confirmed (ideally radiographically), echocardiography is less important for routine 




   SRR is a more useful method of identifying worsening CHF than echocardiographic 
changes (or plasma NT-proBNP measurements, as mentioned previously) (Schober, Hart 
et al. 2011).  
    
   In general, the author recommends repeating echocardiography if the patient’s clinical 
status has changed, rather than at routine, pre-specified intervals, similar to the 
recommendations for repeating radiography outlined above. Examples of how 
echocardiography can contribute valuable information in this setting include the 
identification of a ruptured chorda tendineae causing acute decompensation of CHF or the 
development of pulmonary hypertension leading to the development of right-sided 
congestive heart failure. 
g) Lung Ultrasound 
Lung ultrasound is a useful method to identify extravascular fluid in the lungs and is 
commonly used as an adjunct to echocardiography in patients with CHF and a 
standardised examination protocol, known as Vet BLUE, has been described (Lisciandro, 
Fosgate et al. 2014, Vezzosi, Mannucci et al. 2017). Normal air-filled lung creates 
reverberation artefacts on ultrasound, known as A lines, which appear as horizontal lines 
across the image. In contrast, the presence of fluid in the lungs creates B lines on 
ultrasound, also known as comet tail artefacts or lung rockets, which are orientated 
parallel to the ultrasound beam. Dogs and cats with healthy lungs have very few or no B 
lines on lung ultrasound; in contrast, patients with CHF have large numbers of B lines 
(Lisciandro, Fosgate et al. 2014, Lisciandro, Fulton et al. 2017). Lung ultrasound can be 
performed quickly, with the patient standing or in sternal recumbency and with minimal 
restraint; this technique is therefore particularly suitable for dyspnoeic, unstable patients. 




to allow assessment for changes consistent with significant cardiac disease and right-
sided CHF (e.g. atrial enlargement, decreased ventricular systolic function and the 
presence of pericardial and/ or pleural effusions). Additionally, a brief abdominal 
ultrasound examination will allow detection of ascites. 
It is important to remember that B lines are also seen in other causes of increased 
extravascular fluid in the lungs, including pneumonia and haemorrhage; thoracic 
radiography therefore remains the preferred modality for definitive differentiation of 
cardiac from non-cardiac causes of respiratory distress. Nevertheless, if significant 
numbers of B lines are seen in combination with left atrial enlargement in a patient 
presenting with respiratory distress, it is reasonable to instigate treatment for CHF. This is 
especially true in patients that cannot tolerate lateral recumbency due to dyspnoea and are 
too unstable to be restrained for radiography; many cats will fall into this category. A 
positive response to diuretic therapy usually confirms the presence of CHF and further 
investigations, such as more extensive echocardiography and thoracic radiography, can be 
performed once the patient is more stable. 
h) Specific Monitoring Considerations for Right-Sided Congestive Heart Failure 
Much of the advice given above applies equally to the monitoring of left- and right-sided 
CHF, particularly the recommendations for monitoring of BP, hydration status, renal 
parameters and electrolytes. It is also important to remember that cats with left-sided 
heart disease often present with pleural effusions. However, there are some differences, 
which are outlined below. 
i) Thoracic and abdominal ultrasound are excellent modalities for the identification 
and monitoring of pleural and pericardial effusions and ascites, with the advantage 




ii) Ascites is typically better tolerated than pulmonary oedema or significant pleural 
effusion and will consequently have less impact on SRR until a large enough 
volume has accumulated to significantly compromise breathing. 
iii) Measurement of the abdominal circumference can be a useful method for at home 
monitoring of ascites. 
iv) The presence of significant arrhythmias (e.g. rapid atrial fibrillation) or pericardial 
effusion typically results in right-sided CHF. 
 
Frequency of Monitoring 
As with any clinical test, the clinician should always consider how the results will guide their 
therapeutic plan. If the plan will remain unchanged regardless of the results, then the clinician 
should question their motivation for performing the test. This is particularly important in the 
case of cats, as the benefit of any monitoring test must outweigh the potential risk of 
decompensation inherent in exposing the patient to the stress of a visit to the clinic. With 
these principles in mind, it is clear that any monitoring plan should ideally be tailored to the 
clinical needs of the patient; a cat that has a stable SRR, good appetite and good energy levels 
but becomes very stressed when presented to the clinic would be monitored less frequently 
than a dog with uncontrolled CHF and rapid atrial fibrillation that tolerates clinic visits well. 
Nevertheless, some general principles are outlined in Table 1. 
 
Summary 
Dogs and cats can continue to have a good quality of life for months or even years after the 
onset of congestive heart failure. However, judicious monitoring is important to optimise 




potential adverse effects of treatment, including excessive dehydration, hypotension, 
azotaemia and electrolyte abnormalities, and the negative effects of the underlying cardiac 
disease, such as cachexia. Ideally the monitoring regime should be tailored to the needs of the 
individual patient, with tests being performed in order to answer specific clinical questions, 
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Table 1: Recommendations for monitoring of congestive heart failure in dogs and cats. 
Monitoring test Frequency 
Sleeping respiratory 
rate 
Daily (or more frequently if concerned about increases or upward 
trends) 
Blood tests PCV/TS, renal 
parameters and 
electrolytes:  
• Ideally at the onset of CHF 
• 5-7 days after initial stabilisation of CHF 
• 5-7 days after adjusting medications 
(especially diuretics and ACEi) 
• Every 3-6 months thereafter 
Cardiac biomarkers • Ideally at the onset of CHF 
• 5-7 days after initial stabilisation of CHF 
• Consider measurement every 6 months 
(some evidence of prognostic value) 
Blood pressure 
measurement 
• At each clinic visit 
• If clinical signs develop that are potentially referable to 
hypotension (e.g. weakness or syncope) 
Electrocardiography Standard ECG • If an arrhythmia is detected on physical 
examination 
• If clinical signs potentially referable to a 







• If clinical signs potentially referable to an 
arrhythmia are reported 
• 7-14 days after initiation of 
antiarrhythmic therapy 
• 7-14 days after any dose adjustment of 
antiarrhythmic drugs 
Radiography • If new or worsening clinical signs develop, especially those 
potentially referable to the respiratory system 
Echocardiography • If new or worsening clinical signs develop, especially those 
potentially referable to deterioration in cardiac function (e.g. 







Figure 1: An illustration of Starling’s forces under normal conditions. At the proximal end of 
the capillary (on the left of the diagram), the lower oncotic pressure in the interstitium created 
by the lower protein concentration favours extravasation of fluid. At the distal end of the 
capillary (on the right of the diagram), the lower intravascular hydrostatic pressure favours 
movement of fluid back into the capillary. However, if pulmonary venous pressure increase, 
the distal capillary hydrostatic pressures also increase, preventing this inward movement of 













Figure 3: Lateral and ventrodorsal radiographs of the thorax of a dog with cardiomegaly, pulmonary 
venous congestion and a caudodorsally distributed heavy interstitial to alveolar pulmonary pattern, 
consistent with cardiogenic pulmonary oedema. These are the three changes typically seen in dogs 







Figure 4: A Holter ECG monitor. 
 
 
